R&G PharmaStudies Co. Ltd. A (301333.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · China · ISIN CNE100005K44

Price
56.73 CNY
Market cap
5.48 bn CNY
P/E (2025)
40.02
P/S (2025)
6.44
Dividend yield
0.28 %
Net margin
16.09 %
Return on equity (ROE)
6.96 %
Return on assets (ROA)
5.71 %

R&G PharmaStudies Co. Ltd. A financials

Fiscal year20242025
Revenue744.00 m CNY851.01 m CNY
Gross profit275.92 m CNY295.64 m CNY
Operating income130.49 m CNY135.02 m CNY
EBIT161.23 m CNY158.01 m CNY
Net income140.22 m CNY136.90 m CNY
Diluted EPS – continuing operations1.45 CNY1.42 CNY

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About R&G PharmaStudies Co. Ltd. A

R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology services. It serves pharmaceutical and medical device companies, and scientific research institutions. The company was founded in 2008 and is headquartered in Beijing, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.